The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline

Core Viewpoint - UroGen Pharma Ltd. is facing a class action lawsuit due to allegations of misleading statements regarding the effectiveness of its lead pipeline product, UGN-102, during the class period from July 27, 2023, to May 15, 2025 [3][4]. Group 1: Allegations - The complaint claims that the ENVISION clinical study was inadequately designed, lacking a concurrent control arm, which undermines the evidence of UGN-102's effectiveness [3]. - It is alleged that UroGen Pharma did not heed FDA warnings about the study design, leading to a substantial risk that the New Drug Application (NDA) for UGN-102 would not be approved [3]. - The lawsuit asserts that the company's positive statements regarding its business and prospects were materially misleading and lacked a reasonable basis due to the aforementioned issues [3]. Group 2: Class Action Details - Shareholders who purchased URGN shares during the specified class period are encouraged to register for the class action, with a deadline set for July 28, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4]. - There is no cost or obligation for shareholders to participate in the class action [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].